Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
SKYE Skye Bioscience Inc
- Stocks
- Healthcare
- NASDAQ: SKYE
Price (delayed)
$1.87
Market cap
$57.94M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.83
Enterprise value
$11.93M
Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I
Highlights
Skye Bioscience's debt has shrunk by 91% YoY and by 10% QoQ
The company's quick ratio has surged by 90% YoY but it fell by 29% QoQ
SKYE's EPS has surged by 74% year-on-year but it is down by 14% since the previous quarter
The equity has contracted by 25% YoY and by 13% from the previous quarter
Key stats
What are the main financial stats of SKYE
Market
Valuations
Earnings
Shares outstanding
30.98M
Market cap
$57.94M
Enterprise value
$11.93M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.98
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$35.8M
Net income
-$32.65M
EBIT
-$32.33M
EBITDA
-$31.88M
Free cash flow
-$31.32M
Per share
Balance sheet
Liquidity
EPS
-$0.83
EPS diluted
-$0.83
Free cash flow per share
-$0.79
Book value per share
$1.91
Revenue per share
$0
TBVPS
$1.63
Total assets
$64.79M
Total liabilities
$5.54M
Debt
$412,111
Equity
$59.25M
Working capital
$57.71M
Debt to equity
0.01
Current ratio
11.85
Quick ratio
11.13
Net debt/EBITDA
1.44
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-42.6%
Return on equity
-47.3%
Return on invested capital
-1,549.4%
Return on capital employed
-54.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SKYE stock price
How has the Skye Bioscience stock price performed over time
Intraday
-6.97%
1 week
3.31%
1 month
18.35%
1 year
-84.73%
YTD
-33.92%
QTD
17.61%
Financial performance
How have Skye Bioscience's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$35.8M
Net income
-$32.65M
Gross margin
N/A
Net margin
N/A
Skye Bioscience's net income has decreased by 23% QoQ but it has increased by 13% YoY
SKYE's operating income is down by 19% from the previous quarter but it is up by 5% YoY
Price vs fundamentals
How does SKYE's price correlate with its fundamentals
Growth
What is Skye Bioscience's growth rate over time
Valuation
What is Skye Bioscience stock price valuation
P/E
N/A
P/B
0.98
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
SKYE's EPS has surged by 74% year-on-year but it is down by 14% since the previous quarter
SKYE's P/B is 42% below its last 4 quarters average of 1.7
The equity has contracted by 25% YoY and by 13% from the previous quarter
Efficiency
How efficient is Skye Bioscience business performance
The company's return on equity has surged by 78% YoY but it fell by 32% QoQ
The ROA has soared by 65% YoY but it has decreased by 35% from the previous quarter
Dividends
What is SKYE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SKYE.
Financial health
How did Skye Bioscience financials performed over time
The current ratio has soared by 98% YoY but it has contracted by 27% from the previous quarter
The company's quick ratio has surged by 90% YoY but it fell by 29% QoQ
Skye Bioscience's debt is 99% lower than its equity
Skye Bioscience's debt has shrunk by 91% YoY and by 10% QoQ
The debt to equity has plunged by 83% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.